Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
GLP-1 demand is reshaping supplements. PureHealth Research’s berberine launch tests where wellness claims meet evidence and regulation.
GLP-1 drugs dominate obesity. GSK is betting SiranBio’s SA030 can attack visceral fat risk from a different angle.
Novo Nordisk has the first-mover pill. Eli Lilly has the growth aura. Oral obesity drugs are turning access into the next GLP-1 battleground.
Canada has generic Ozempic momentum. Apotex’s approval turns GLP-1 access into a pricing and supply-chain test.
MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.